2014 Fiscal Year Final Research Report
Regulation of GVHD by HGF displaied lactobacillus
| Project/Area Number |
24590227
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Hyogo University of Health Sciences |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SANO Hajime 兵庫医科大学, 医学部, 教授 (00196304)
SHIBASAKI Seiji 兵庫医療大学, 共通教育センター, 准教授 (50342530)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MATSUMOTO Kunio 金沢大学, がん研究所, 教授 (90201780)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 肝細胞増殖因子 / 移植片対宿主病 / 酵母 / 分子ディスプレイ法 |
|---|
| Outline of Final Research Achievements |
We previously established hepatocyte growth factor (HGF) gene therapy to treat acute graft-versus-host disease (GVHD), preserve graft-versus-anti-leukemic (GVL) effect, and to recover T cell immunity. However, gene transfection and intravenous administration of HGF cannot supply sufficient amount of HGF to injured organs caused by GVHD. We tried to administer HGF displayed Yeast orally and to directly supply high concentration of HGF to injured intestine. Oral administration of yeast expressed HGFαand βchain into graft-versus-host disease (GVHD) model mice reduced clinical symptoms such as skin inflammation and prolonged their survival. Histopathological examination revealed that intestinal epithelial cell injuries were inhibited by this treatment. Inflammatory cytokine expressions in the liver, intestine, and spleen were reduced by this treatment. HGF-displayed yeast can therefore be potentially applied as a novel therapeutic approach for the treatment of GVHD.
|
| Free Research Field |
血液・免疫学
|
